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Abstract
Background: The focus in recent years on physical inactivity and metabolic disturbances in individuals with
schizophrenia raises the question of potential effects of physical activity. Physical activity has shown beneficial
effects on cognition in healthy older individuals as well as on symptom severity in depression. However, opinions
diverge regarding whether aerobic high-intensity interval training reduces cognition and key symptoms in
schizophrenia. The main objective for the trial is to investigate the potential effects of aerobic high-intensity interval
training on neurocognitive function and mental symptoms in outpatients with schizophrenia.
Methods/Design: The trial is designed as a randomized controlled, observer-blinded clinical trial. Patients are
randomized to 1 of 2 treatment arms with 12-week duration: aerobic high-intensity interval training or computer
gaming skills training. All participants also receive treatment as usual. Primary outcome measure is neurocognitive
function. Secondary outcome measures will be positive and negative symptoms, wellbeing, tobacco-smoking
patterns and physiological/metabolic parameters. Patient recruitment takes place in catchment area-based
outpatient clinics.
Trial registration: ClinicalTrials.gov NCT02205684. Registered 29 July 2014.
Keywords: High-intensity interval training, Schizophrenia, Psychosis, Neurocognition
Background
Schizophrenia is a severe mental illness characterized
by delusions and hallucinations (i.e. positive symp-
toms), affect flattening, poverty of speech, lack of
motivation and social withdrawal (i.e. negative symp-
toms) and cognitive impairment, making it one of the
leading causes of disability in the age group 15–44
years [1–3].
People with schizophrenia are more likely to smoke
[4], to be physically inactive [5], suffer from malnutrition
due to an unhealthy diet [6] and have low cardiorespira-
tory fitness (CRF) [7–9]. They commonly also suffer
from comorbid psychiatric disorders such as depression
as well as substance misuse [10] and manifest multiple
somatic comorbidities [11]. Compared to healthy indi-
viduals there is a 2.5 to 4.0-fold increase in prevalence of
the metabolic syndrome [12–14] and a 20 % reduction
in life expectancy in individuals with schizophrenia.
Antipsychotic medication is a cornerstone in the treat-
ment of schizophrenia, substantially reducing symptom
severity and relapses [15]. However, antipsychotics are
most effective in reducing positive symptoms, and they
have minimal effect on negative symptoms or cognitive
function [16]. Psychosocial interventions (e.g. cognitive
behavior therapy, cognitive remediation therapy, family
psychoeducation, social skills training, supported em-
ployment) are usually provided in addition to pharmaco-
logical treatment and play an important role in the
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treatment of schizophrenia, especially in improving daily
life functioning.
Among healthy individuals, physical activity has positive
effects on physical health, mental health and cognition.
Moreover, positive effects of physical activity have also
been described for persons with mental disorders, such as
depression [17–20]. High-intensity interval training is
shown to increase CRF and reduce the risk of various
somatic illnesses [21, 22] and is established as a safe and
useful exercise method. For people with schizophrenia
evidence is sparse with regard to the effect of physical
activity, in particular on post-exercise psychological states
or neurocognition. A recent randomized controlled trial
(RCT) investigated the effect of an aerobic exercise pro-
gram in 33 individuals with schizophrenia (aerobic exer-
cise, n = 16; treatment as usual, n = 17) [23]. After
completion of the 12-week exercise program (1 hour each
session, 3 times weekly) the aerobic exercise group
showed a significant improvement compared to the con-
trol group. The effects of combined interventions were ex-
amined in a non-randomized study of 43 individuals with
schizophrenia [24]. The participants were exposed to ei-
ther endurance training (n = 22) or a control condition
playing table soccer (n = 21). During the last half of the
12-weeks intervention the individuals in both groups also
attended a cognitive remediation program. Significant im-
provements were found in short-term and long-term ver-
bal memory and cognitive flexibility from the start of the
combined intervention at week 6 to the end of the 3-
month training period in the group exposed to endurance
training augmented with cognitive remediation. However,
conclusions concerning the effects of each component in
the combined intervention are hard to draw due to the
design of the study.
Recent reviews have called for well-designed studies to
explore these important topics further [25–27]. Interpret-
ation of previous studies investigating effects of regular
sport activities lasting for weeks or months have been
hampered by small sample sizes [28–30]. In the largest
study to date, 20 patients with schizophrenia met compli-
ance demands and received exercise therapy 1 to 2 hours
a week for 6 months in the experimental group. When
compared to 19 patients in the control condition receiving
occupational therapy [8] significant effects were found on
positive and depressive symptoms, as well as trend level
decrease for negative symptoms in per protocol analyses.
The total attrition rate was 38 %, and in the intention-
to-treat analysis no significant effects were found.
The cardiovascular fitness hypothesis [31] suggests
that CRF is a physiological mediator that explains the
various mental health benefits of physical activity. In re-
gard to cognitive functions, CRF might be more benefi-
cial for individuals with limits on their cognitive reserves
[32], such as people with schizophrenia. A finding of
exercise-induced increase in hippocampal volume in
patients with schizophrenia and a positive correlation of
volume increase and short-term memory improvement
supports this hypothesis [33].
Low CRF increases the risk of cardiovascular disease
(CVD) [34, 35], which is the largest single cause of
death in schizophrenia [36]. This, taken together with
an unhealthy lifestyle, underscores the need for multi-
disciplinary treatment and underlines the need for
addressing physical activity and, in particular, high-
intensity interval training, which is more effective than
moderate intensity exercise in increasing CRF in the
short term [37, 38].
Many exercise intervention studies for persons with
mental disorders have methodological limitations, which
makes it difficult to draw firm conclusions. The most
common limitations are small sample sizes, that the
randomization process has not been undertaken at a site
remote from where the intervention takes place, lack of
blinded assessment of outcome, imprecise assessments
(if any) of CRF, low adherence to the exercise proto-
cols, lack of long- term follow-up assessment, and
not analyzing the data according to the intention-to-
treat principle [39].
There is currently insufficient evidence to know whether
regular high-intensity interval training reduces key symp-
toms in schizophrenia. Studies with larger sample sizes
comprised of participants adhering to the exercise proto-
col are needed.
We aim to conduct a trial where these methodological
considerations are addressed by comparing a 12-week
aerobic high-intensity interval training (HIIT) program
to skills training of the same duration, with regard to: 1)
aspects of cognitive function, especially memory, atten-
tion and executive function, and 2) psychiatric symptom
load (negative and positive symptoms) and wellbeing.
Post-treatment improvement in cognition and psychotic
symptoms are anticipated. We hypothesize that the indi-
viduals in the Exercise Group (EG) will perform better
than individuals in the Computer Skills Group (CSG) on
aspects of cognitive function, especially memory, attention
and executive function. In addition, we expect ameliorated
positive and negative symptoms in the EG.
The effects of HIIT on maximum oxygen uptake and
risk factors for CVD (i.e. tobacco- smoking, elevated
blood pressure, dyslipidemia, insulin resistance and high
body fat) are also subject to investigation.
Methods
Trial design
This trial is designed as a randomized controlled, paral-
lel group, observer-blinded clinical trial (Fig. 1).
Participants are randomized to either a high-intensity
interval group (Exercise Group, EG) or to a comparison
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group (Computer Gaming Skills Group, CSG). Dur-
ing the 12-week interventions treatment as usual is
continued for all patients. Patients are assessed at
the start (T0) and end of the intervention (T1) as
well as at 4 months post-treatment (T2). The trial is
observer-blinded, as measurement of psychiatric
symptoms and neurocognitive function is performed
by research staff blinded for group allocation. The
researchers are geographically dispersed from the
training facilities. When assessed after training, the
participants are instructed not to disclose what activ-
ity they have taken part in. The physiological testing
is performed by staff involved in delivery of the interven-
tions and will not be blinded except at baseline. The same
holds for collecting self-ratings involving measures of
activity.
Recruitment and eligibility
The participants are outpatients at the psychiatric re-
habilitation clinics in Tønsberg (Nordre Vestfold dis-
triktspsykiatriske senter, NVDPS) and Larvik (Søndre
Vestfold distriktspsykiatriske senter, SVDPS) in Vestfold
County. The clinics are part of the Division of Mental
Health and Addiction in Vestfold Hospital Trust, Norway.
The outpatient clinics are catchment area-based and cover
a total population of approximately 200,000 people. Pa-
tient inclusion started in August 2014 and will continue
until October 2016. Eligible for the study are outpatients
who fulfill the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-V) criteria for schizophrenia spectrum
disorder (schizophrenia, schizoaffective disorder and schi-
zophreniform disorder). Inclusion and exclusion criteria
are presented in Table 1. Participation will be terminated
if any of the exclusion criteria occurs (for instance preg-
nancy) during the trial or if the participant withdraws the
informed consent.
Diagnosis
The diagnoses are based on the Structured Clinical
Interview for Diagnostic and Statistical Manual of Mental
Disorders (DSM-V) axis I disorders [40]. All interviewers
engaged in diagnostics participate in supervised diagnostic
evaluation meetings on a regular basis.
Fig. 1 Flow chart – participants in the Effects of Physical Activity in Psychosis (EPHAPS) trial
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Intervention
The exercise sessions will be conducted at the Buskerud
and Vestfold University College and the computer gaming
at a local high school in Tønsberg. Supervision of partici-
pants in the two groups is carried out by the same
personnel employed in the outpatient clinics and dedi-
cated to the project throughout the data collection period.
The time spent with activities, as well as time spent with
the intervention staff, is the same in both groups, and a
specific time schedule is followed by the staff to ensure
that each session in the exercise and comparison groups
last 45 minutes. Participants in both groups are also ac-
companied by the project personnel during transportation,
during the sessions of the intervention and during breaks.
The exercise sessions consist of supervised walking/run-
ning on a treadmill twice per week for 12 weeks. Each
session will have the following structure; 8-minute warm-
up, followed by 4x4 minute intervals with 85–95 % of
maximum heart rate, with active pauses of 3 minutes
walking/running at approximately 70 % of maximum
heart rate. Heart rate will be measured and controlled
continuously throughout the exercise session by research
personnel with a heart rate monitor (RCX3 heart monitor
from Polar (Polar Electro Oy, 90440 Kempele, Finland)) to
ensure that the participants intervals and active pauses are
performed with the desired intensity. The exercise session
will end with a 5-minute cool-down period. The goal is to
have the participants adhere to the protocol. However, we
realize that some participants might have difficulties with
this intensive program in the beginning of the interven-
tion, and, thus, the protocol will be individualized and
progressive both in terms of the number of intervals
and the intensity. This high-intensity exercise per-
formed as 4x4 minute intervals has previously been
shown to be feasible, safe and effective for individuals
with schizophrenia [41] and other clinical populations
[21, 22, 26, 27, 38].
Participants in the comparison group take part in
sessions performing computer-simulated sports activities
(Nintendo Wii Sports (Nintendo, Frankfurt am Main,
Germany) tennis, baseball, golf, bowling). Physiological
responses (i.e. oxygen consumption, cardiac output,
metabolic rate) of Nintendo Wii tennis (and baseball)
has shown to be lower than brisk treadmill walking
when tested in bouts of 10 minutes [42]. Through com-
paring neurocognitive and symptom scores in a group
that is physically active with the performance of a
group that simulates such activity, we expect to be able
to extract the net effect of high-intensity exercise.
Changes in simulated sports skills are monitored and
continuous feedback is given to the participants by
supervising personnel.
Treatment as usual
All participants are registered outpatients at the psychi-
atric rehabilitation clinics in Tønsberg (NVDPS) or
Larvik (SVDPS) in Vestfold County and receive individ-
ual treatment during project participation. The treat-
ment is based on appointments at the clinic and/or
home visits, and may include pharmacological treat-
ment, individual psychotherapy, family interventions,
and general psychosocial support through extensive
collaboration with primary care health services. Episodes
of illness exacerbation may require acute or planned ad-
mittance to local or county-level inpatient units, usually
of short-term duration, while remaining registered at the
outpatient clinic and continuing project participation.
Feasibility study
A feasibility study was conducted from November 2013
through January 2014. Participants were outpatients at
NVDPS Tønsberg and had present or previous psychotic
symptoms. Apart from minor alterations, the same study
protocol was followed as in the main trial. The interven-
tion period was, however, considerably shorter, ranging
from 3 to 6 weeks. Group assignment was not random-
ized in the feasibility study, and the raters were not
blinded. Ten patients, 6 men and 4 women, aged 22–64
years (mean age 41) completed the study; 6 in the EG
and 4 in the comparison group. The main purpose of
the feasibility study was to gain experience with practical
aspects of the protocol, evaluating its viability through
particular focus on feedback from participants.
Assessments
Participants will be assessed at three time points. The con-
tent of the assessments are outlined in Table 2. The first
assessment occurs at baseline (T0) prior to randomization,
because information from the baseline assessment is
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Age between 18 and 67
Understand and speak a Scandinavian language
Fulfill the DSM-V criteria for schizophrenia spectrum disorder
(schizophrenia, schizoaffective disorder and schizophreniform disorder)
Exclusion criteria
Pregnancy
Chest pain during exercise
Unstable angina pectoris
Recent myocardial infarction
Uncontrollable cardiac arrhythmia
Severe hypertension (>180/110 mmHg)
Comorbid diagnosis of mild mental retardation
Medical conditions incompatible with participation
DSM Diagnostic and Statistical Manual of Mental Disorders
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Table 2 Assessments in the Effects of PHysical Activity in PSychosis (EPHAPS) trial
Enrollment Baseline Randomization Follow-up 1 Follow-up 2
TIME POINT T0 0 T1 12 weeks T2 28 weeks
ENROLLMENT
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS
Exercise Group (EG) >—————————————<
Computer Gaming Skills Group (CSG) >—————————————<
ASSESSMENTS
General assessments
Sociodemographic data X
Changes in employment status X X
Information on tobacco, dietary habits and current level of physical activity X
Changes in use of tobacco, dietary habits, medication X X
Somatic health
Physical examination: height; electrocardiography (ECG); medication record X
Weight, waist circumference, blood pressure X X X
Changes in medication X X
Body composition assessment (bioelectrical impedance analysis/Tanita-weight) X X X
Blood analyses: glucose, HbA1c, C-peptide, lipids (total cholesterol, HDL, LDL,
TGA), homocystein, prolactin, T4, TSH, BDNF
X X X
Spirometry (pulmonary function test) X X X
Cardiorespiratory fitness, physical activity and sleeping habits
Maximal oxygen consumption X X X
ActiGraph accelerometers (4 days) X X X
Attitudes towards physical activity (PA) X
Change in attitudes towards PA (two selected items from Attitudes towards PA) X X
International Physical Activity Questionnaire (IPAQ) X X X
Assessment of insomnia: Insomnia Severity Index (ISI) X X X
Psychoactive substance use
Selected parts of European Addiction Severity Index (EuropASI) X X X
SCID section E X
Alcohol and Drug Use Disorder Identification Test (AUDIT and DUDIT) X
Alcohol and Drug Use Scale (AUS and DUS) X X X
Fagerström test for Nicotine Dependence (FTND) X X X
Saliva samples for assessing recent intake of tobacco, alcohol, illegal
drugs and legal medication with abuse potential
X X X
Neurocognitive tests
General Ability Index (GAI, Wechsler Adult Intelligence Scale-version 4) X X X
The Emotional Biological Motion Test X X X
Matrics Consensus Cognitive Battery (MCCB) X X X
Diagnostics/symptoms/wellbeing
The Structural Clinical Interview DSM-IV for axis I disorders (SCID-I) X
The Positive and Negative Syndrome Scale (PANSS) X X X
The Psychotic Symptom Rating Scale (PSYRATS) X X X
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needed for validation of the inclusion and exclusion
criteria and required for the stratification. The second
assessment takes place immediately after completion of
the intervention (T1). Longer-term outcomes or possible
delayed effects not evident already at intervention
cessation are tested in the third assessment 4 months
post-treatment (T2).
Neurocognitive function is the primary outcome in
the trial. Secondary outcome measures are positive and
negative symptoms, wellbeing, as well as smoking
habits, and somatic health parameters such as pulmon-
ary function, body mass composition (e.g. body fat,
bone mass), blood pressure, abdominal circumference,
serum lipids, blood glucose. Brain-derived neurotrophic
factor (BDNF), an important biomarker for neuroplasti-
city that seems to be upregulated after physical activity
in schizophrenia [23] is also a secondary outcome
measure. The changes in symptom level, wellbeing,
neurocognitive scores and physiological (e.g. maximum
oxygen uptake) and metabolic indices are assessed from
T0 to T1 and from T1 to T2.
Symptoms, affect and wellbeing
Psychosis symptoms are assessed using the Positive and
Negative Syndrome Scale for Schizophrenia [43]. Charac-
teristics of delusions and hallucinations are specified using
The Psychotic Symptom Rating Scale (PSYRATS, [44]),
also targeting the distress dimension of these symptoms at
baseline and changes therein between T0 and T1 and be-
tween T1 and T2 respectively. For endorsement of pa-
tients’ beliefs, emotions and behaviour related to auditory
hallucinations, the revised Beliefs About Voices Question-
naire (BAVQ-R, [45, 46]) is applied. Participants’
depressive thinking is assessed by the Calgary Depres-
sion Scale for Schizophrenia (CDSS) [47, 48].
The degree of positive feelings towards oneself, life and
future is not necessarily dependent on the occurrence and
intensity of symptoms, even in the realm of severe, psych-
otic disorders. The dominating emotional tone of the
present is assessed by The Positive and Negative Affect
Schedule (PANAS), comprised of two statistically largely
independent scales [49, 50]. The self-report is adminis-
tered to all patients in both intervention groups at T0, T1
and T2, and, for measuring possible immediate effects,
mid-intervention, after completing scheduled activity on a
particular day, in addition to the PANAS assessment im-
mediately after neurocognitive testing at T2. Self-esteem is
assessed using a self-rating scale (Ad Morrison). General
symptoms are appraised using the Clinical Global Impres-
sion Scale (CGI, [51]). Wellbeing is assessed using the 5-
item self-report World Health Organization-5 (WHO-5)
Well-Being Index [52]. The questionnaire has previously
been used to monitor treatment in affective disorders [53].
Neurocognitive tests
Neurocognition is assessed with the Matrics Consensus
Cognitive Battery (MCCB), which is developed particu-
larly for assessment of treatment changes in schizophre-
nia. It assesses cognitive function in seven domains,
including those most probable to increase as a function
of increased cardiorespiratory fitness (executive func-
tions, attention and memory) and offers parallel forms
for repetitive testing. MCCB has been used in previous
studies in Norway and the Norwegian Version has
retained the original psychometric properties [54] with
the possible exception of the test intended to measure
Table 2 Assessments in the Effects of PHysical Activity in PSychosis (EPHAPS) trial (Continued)
The revised Beliefs About Voices Questionnaire (BAVQ) X
Positive and Negative Affects Schedule (PANAS) X X X
Depression: Calgary Depression Scale for Schizophrenia (CDSS) X X X
WHO-5 Well-Being Index X X X
Self-esteem (Ad Morrison)
Clinical Global Impression Scale (CGI) X X X
Psychosocial functioning
Global Assessment of Functioning (GAFs and GAFf) X X X
Quality of Life (Strauss Carpenter Level of Function (SCLOF)) X X X
Insight/adherence/apathy
Insight of illness: Birchwood Insight Scale; cognitive insight:
Beck Cognitive Insight Scale
X X X
Adherence to treatment: The Believes about Medicines Questionnaire (BMQ) X X X
Apathy: Apathy Evaluation Scale (AES) X X X
The table depicts specific time points in the trial for enrolment, intervention (groups and duration), and the assessments
BDNF brain-derived neurotropic factor, HbA1c glycosylated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, T4 thyroxine, TGA triglycerides,
TSH thyroid stimulating hormone
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social cognition. This subtest will be replaced by The
Emotional Biological Motion Test [55], which is an
experimental test newly developed by leading research
groups in this field. At baseline participants will be
examined with 6 subtests from the Wechsler Adult
Intelligence Test-version 4, resulting in a General Ability
Index-score equivalent to a full scale IQ.
Sociodemography
Basic sociodemographic data is collected, including sex,
age, education, marital status, employment, living condi-
tions, etc.
Lifestyle
Basic lifestyle parameters are assessed, including dietary
habits, daily activity level, and daily use of stimulants
containing caffeine and nicotine. Psychoactive substance
use is thoroughly covered; see below.
Somatic health
A physical examination with medication record is under-
taken in the trial. All participants are examined with
electrocardiography (ECG). General health parameters
such as weight, waist circumference and blood pressure,
as well as pulmonary function and body composition are
assessed. Blood samples, which encompass standard
blood tests in addition to BDNF, will be collected from
participants following overnight fasting at the three
assessment points. For analysis of BDNF venous blood
samples are collected in tubes containing ethylenedi-
aminetetraacetic acid (EDTA). After centrifugation at
2500 g for 20 minutes, platelet-poor plasma will be
isolated, aliquoted and stored at −80 °C. At the end of
data collection, all samples will be analyzed for BDNF
concentrations using enzyme immunoassay at the Re-
search Institute for Internal Medicine, Rikshospitalet,
Oslo, Norway.
Cardiorespiratory fitness, physical activity and sleeping
habits
Maximal oxygen uptake (VO2max) is measured during a
maximum exercise test on a treadmill using a modified
Balke protocol [56]. Gas exchange is sampled continu-
ously into a mixing chamber every 30 s by having the
participants breathe into a Hans Rudolph 2-way breath-
ing valve (2700 series, Hans Rudolph Inc., Kansas City,
MO, USA) connected to a Jaeger Oxycon Pro gas
analyzer (Erich Jaeger GmbH, Hoechberg, Germany),
which measures the oxygen and carbon dioxide content.
Physical activity level is measured both objectively (Acti-
Graph accelerometer GT3X+ (ActiGraph, Pensacola, FL,
USA) worn on the hip for 4 consecutive days; 2 weekdays
and 2 days of the weekend) and subjectively using the
International Physical Activity Questionnaire (IPAQ, short
form [57, 58]). In addition, potential psychosocial media-
tors for change in physical activity and attitudes towards
physical activity will be measured by previously developed
and validated scales: social support for physical activity
[59, 60], self-efficacy and outcome expectancies and
attitudes [61, 62]. Sleeping habits are assessed using the
ActiGraph data as well as the brief Insomnia Severity
Index (ISI, [63]).
Psychoactive substance use
At baseline, a diagnostic assessment of psychoactive
substance use is performed with the SCID section E
(including alcohol, illegal drugs and legal drugs with
abuse potential), and the severity of such use is addition-
ally measured with the Alcohol and Drug Use Disorder
Identification Tests (AUDIT [64] and DUDIT [65]).
Assessments at 3 time points (T0/T1/T2) will include
selected parts of the European Addiction Severity Index
(EuropASI) [66], Alcohol [67] and Drug Use Scales [68]
(AUS and DUS respectively), Fagerström test for Nico-
tine Dependence [69] and saliva samples for assessing
recent intake of tobacco, alcohol, illegal drugs and legal
medication with abuse potential. The toxicological
analyses will be performed at Division of Forensic Toxi-
cology and Drug Abuse Research, Norwegian Institute of
Public Health.
Psychosocial functioning, adherence and insight
Strauss Carpenter Level of Functioning Scale (SCLOF) is
utilized for the endorsement of patients’ social and work
functioning. Global Assessment of Functioning (GAF,
[70]) is divided into two scales measuring symptoms
(GAFs) and function (GAFf) to improve psychometric
properties [71]. Insight of illness (Birchwood Insight
Scale, IS, [72]), cognitive insight (Beck Cognitive Insight
Scale, BCIS, [73]) and apathy (Apathy Evaluation Scale,
AES, [74]) are assessed using self-rating scales.
Protocol deviations
When absent from scheduled exercise or computer
gaming, the participant will be contacted and offered to
participate on a following day the same week. Partici-
pants who fail to complete at least 60 % of the total
number of intervention sessions or have not participated
for more than 2 successive weeks are considered proto-
col violators. Participants who are unable to meet for the
VO2max test within 10 days following the last training
session will also be considered protocol violators.
However, they will be allowed to stay in the study and
will be tested as soon as possible, as well as invited to
take part in T2. Statistical analyses will be performed
both based on the principle of “intention-to-treat”
including everyone regardless of protocol violations, but
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“per protocol” analyses will also be executed, comparing
only those who completed the two treatment conditions
according to the protocol.
Sample size calculations
We assume that the outcome measures are continuous
variables with a normal distribution, and two independent
clinical groups are being compared. Estimates of statistical
power are calculated for the primary outcome measure.
The neurocognitive tests applied in the study (MCCB
battery) are designed for repeated administrations to test
possible treatment effects. Some improvement must be
expected in both groups because of the treatment/stimula-
tion and as retest effects (being accustomed to the test
design if not the actual test material). Nevertheless, we
expect that the effect size in the EG will be 0.50 standard
deviations (which is a medium effect size) larger than the
increase in the CSG, which given a statistical power of
0.80 and alpha of 0.05 necessitates a sample size of 55 in
each group. The dropout rate in the current study after
randomization and group assignment is estimated to
15 %. Thus, the estimate is that recruitment of 126
participants is needed to secure the participation of
55 individuals in each group. Further attrition at later
stages in the study progress is accounted for by utilizing
the “intention-to treat” analysis.
Randomization and stratification
After the baseline assessments, the participants will be
randomly assigned to either CSG or EG. A computerized
random number generator is utilized to produce the
allocation sequence. Equal distribution of participants in
the two groups on CRF is ensured by stratification on
expected median with regard to scores on VO2max at
baseline. By varying the size of the stratification blocks,
each treatment assignment remains unpredictable. Se-
nior researchers in the project (JAE, JE) generated the
randomization sequence. A dedicated project coordin-
ator, who is not located near the participants during
sessions and not concerned with outcome assessments,
administers the group assignment using the method of
concealed envelopes. The name, date of birth, trial
number and assigned treatment is registered on a log
sheet made for the participant in the trial.
Statistical analysis
Decisions about sample size and design of the project are
primarily aimed at comparing the EG with the CSG. The
main statistical analyses will be variants of analyses of
variance such as Multivariate ANOVA (MANOVA) to test
overall group differences, repeated measures ANOVA to
look for interactions between time and group (i.e. to test
whether the EG have larger change between time points
than CSG). Changes in outcome measures will be
correlated with changes in CRF. Analysis of covariance
will be used to test hypotheses whether the effect of spe-
cific variables extend beyond effects of nonspecific vari-
ables. Baseline data could be analyzed without referral to
later group membership, enabling analyses of empirically
derived subgroups such as participants scoring low or
high on the physiological measures, or participants with
or without concurrent tobacco use. Baseline data will also
be analyzed with regression analyses and correlations/par-
tial correlations controlling for potential confounding
variables.
Data storage and use of statistical tools
The data will be stored and analyzed in the Vestfold
Hospital Trust using the Statistical Package for the
Social Sciences (SPSS version 18.0.1, SPSS inc., Chicago,
IL, USA). Data cleaning will be performed via SPSS
syntax operations (SPSS Inc., Chicago, IL, USA).
Ethical considerations
The project is approved by the Regional Ethics Commit-
tee of Southern and Eastern Norway (REK Sør-Øst)
under file number 2014/372/REK SØR-ØST C. Trial
registration has been carried out at ClinicalTrial.gov
(NCT02205684). Informed and written consent is a pre-
requisite for participation. Initial information about the
study will be given to eligible patients by the regular staff
during a routine appointment in the outpatient clinic, or
by a project co-worker. Further detailed written and oral
information about the trial will then be given by the
project co-worker. It will be assured that participation is
voluntary, that the participants can withdraw at any time
point and will receive ordinary treatment whether they
choose to participate or not. If the patient understands
the nature of the research and is willing to participate,
he or she will be asked to sign a consent form. The
interviews in the trial will be completed in several
encounters with the participant, and emphasis will be
put on avoiding unnecessary strain on the individual and
adjustment to own preferences. Similarly, when taking
part in the treatment intervention, attention will be paid
to the physical fitness of the participant. Potential alter-
ation of the intensity and frequency of the physical activity
will be adjusted individually over several weeks. Partici-
pants experiencing discomfort or possible medical compli-
cations while exercising on the treadmill will receive
immediate necessary examination by medical staff in the
unit. Positive as well as negative results will be published
according to the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [75].
Motivational work
Motivating patients with severe mental disorders, prone
to be insufficiently physically fit to perform high-intensity
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interval training twice a week, is perceived a major
challenge. Although the motivational work is performed
by the intervention staff in informal settings when talking
to participants before and after each session, as well as
during transportation between their home and the project
facilities, it needs to be structured and theory-based. Key
constructs in social cognitive theory [76] are applied (i.e.
opportunities to perform physical activity; social support
for physical activity; confidence to do physical activity;
expected benefits and costs of performing physical
activity; knowledge and skill to perform physical activity;
personal goal setting and monitoring of physical activity),
putting much effort in translating this knowledge into
effective practices.
Adverse events
Medical examination and ECG are performed before the
exercise program starts, and all patients are evaluated as
suitable for training. One potential concern might be the
combination of physical exercise and medication, but
there is no evidence for danger in exercising while using
therapeutic doses of psychotropic medication [77].
Emergency procedures
To minimize the risk of medical emergencies, patients
with a known unstable heart condition (e.g. unstable
angina pectoris and recent myocardial infarction) will be
excluded from the study. Also, ECG and physical examin-
ation performed by a physician are performed before
inclusion in the study. Health staff with specific know-
ledge of cardiopulmonary resuscitation will be present at
all treadmill-sessions of physical testing and exercise. In
case of symptoms such as chest pain and dizziness during
exercise, the session will be discontinued immediately. In
case of symptoms of cardiac arrest (unresponsive person
with no or abnormal breathing), cardiopulmonary resusci-
tation will be initiated immediately and an ambulance will
be called.
Discussion
Physical activity has been shown to reduce symptoms of
depression and increase cognitive functions in other
groups associated with cognitive dysfunction such as
Parkinson’s disease [78, 79] and old age [80–82]. It is,
therefore, plausible that physical activity may have bene-
ficial effects, both on the level of mental symptoms and
cognitive function in schizophrenia, but high-quality
data from RCTs is lacking. In the present study high-
intensity treadmill exercise for 12 weeks is compared to
computer-based skills training, otherwise shown to have
beneficial effects on cognitive function [33]. Well-
validated measures of the respective functional domains
serve as main outcome measures and assessments are
performed pre-training, immediately after completed
training and 4 months post-treatment allowing
appraisal of possible delay between increased CRF and
reduced symptoms. Secondary outcome measures are
related to factors reducing risk of metabolic syndrome
and improving physical health. If we find that intensive
exercise can reduce symptoms and increase cognitive
performance, it may have implications for future treat-
ment of patients with schizophrenia. As cognitive
remediation programs so far have focused on learning
techniques in a top-down fashion [83], documenting
possible bottom-up beneficial effects may open up new
routes for helping these patients increase their cognitive
functions. In regard to symptom reduction, broadening
the armamentarium of methods, primarily consisting of
pharmacological treatment and psychotherapy, to also
contain physical activity, will be welcomed as in-
creased CRF in general has an effect on both morbidity
and mortality.
As the general optimism regarding the positive effects of
physical activity on symptoms and cognition has now
spread from normal aging, treatment of depression to
schizophrenia, resulting in small-scale or non-systematically
researched interventions, the findings of no differential
increase in mental and cognitive functions, may lead to
some disappointment regarding the role of physical activity
in treating these elements of severe mental disorder. Early
death from cardiovascular disorders and reduced function
due to low cardiovascular capacity and low muscular
strength are other important treatable elements of the
schizophrenia group of disorders. It is important that treat-
ment approaches are empirically-based and not merely
plausible inferences from knowledge in other groups. High-
intensity exercise is demanding for the patient, as well as
the help-giving system. Thus, with this level of knowledge,
emphasis should be placed on finding causal effects or
mediating mechanisms, while the cost-effectiveness of
physical activity, as a way to improve functions other
than key symptoms in schizophrenia, is another im-
portant issue.
Perhaps, the greatest challenge conducting an inter-
vention study of this kind is making the participants ad-
here to the demanding exercise regime. To meet this
challenge, participants are given individual tutoring and
motivational talks and are offered project-initiated trans-
portation in order to increase adherence – a support re-
gime which is equally comprehensive in both groups.
Thus, the present trial involves a support system that
would not be sustainable in ordinary clinical work.
In selection of an adequate control condition, it is
important for adherence to the skills training control
group that both the participants and the intervention
staff find the activity meaningful, and by that preventing
an expectancy-related lack of effect in the comparison
group.
Engh et al. Trials  (2015) 16:557 Page 9 of 12
Trial status
The recruitment started August 2014. By April 2015 a
total of 32 subjects were participating. Five subjects have
dropped out of the study. The planned recruitment of
126 participants will be completed by October 2016.
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